Profile data is unavailable for this security.
About the company
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
- Revenue in EUR (TTM)2.14m
- Net income in EUR-21.92m
- Incorporated2004
- Employees54.00
- LocationPhaxiam Therapeutics SA60 avenue RockefellerLYON 69008FranceFRA
- Phone+33 478744438
- Fax+33 478755629
- Websitehttps://erytech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theranexus SA | 0.00 | -3.08m | 3.85m | 12.00 | -- | -- | -- | -- | -0.3971 | -0.3971 | 0.00 | -0.0004 | 0.00 | -- | -- | 0.00 | -50.35 | -42.66 | -64.95 | -47.97 | -- | -- | -- | -- | -- | -420.89 | 1.00 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 0.00 | -9.40m | 5.03m | 3.00 | -- | -- | -- | -- | -0.1519 | -0.1519 | 0.00 | -0.0255 | 0.00 | -- | -- | 0.00 | -282.86 | -60.77 | -422.81 | -102.24 | -- | -3,548.91 | -- | -3,374.13 | -- | -131.78 | 3.97 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -15.86m | 6.63m | 28.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.4011 | 0.00 | -- | -- | 0.00 | -129.36 | -- | -695.94 | -- | -- | -- | -- | -- | -- | -- | 3.71 | -- | -- | -- | -17.40 | -- | -- | -- |
| Predilife SA | 317.79k | -4.22m | 14.20m | 19.00 | -- | -- | -- | 44.69 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Plant Advanced Technologies PAT SA | 2.53m | 1.09m | 14.37m | 27.00 | 12.94 | -- | 9.11 | 5.67 | 0.9967 | 0.9967 | 2.32 | -- | -- | -- | -- | 93,777.41 | -- | -3.53 | -- | -4.39 | 110.03 | 134.21 | 43.01 | -33.16 | -- | 12.90 | -- | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Poxel SA | 1.98m | -35.09m | 14.41m | 22.00 | -- | -- | -- | 7.27 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
| Phaxiam Therapeutics SA | 2.14m | -21.92m | 18.39m | 54.00 | -- | 0.7219 | -- | 8.59 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Valbiotis SA | 527.00k | -8.94m | 18.42m | 52.00 | -- | 1.09 | -- | 34.95 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 19.65m | 19.00 | -- | 6.23 | -- | 41.91 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Nfl Biosciences SAS | 0.00 | -2.37m | 19.99m | 4.00 | -- | 5.75 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
| Fermentalg SA | 8.04m | -14.14m | 27.14m | 58.00 | -- | 0.7075 | -- | 3.38 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
Data as of Nov 12 2024. Currency figures normalised to Phaxiam Therapeutics SA's reporting currency: Euro EUR
1.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Aug 2024 | 95.96k | 0.96% |
| BVF Partners LPas of 28 Mar 2023 | 10.53k | 0.11% |
| Generali Asset Management SGR SpAas of 30 Dec 2022 | 7.57k | 0.08% |
| Gestys SAas of 30 Aug 2024 | 6.00k | 0.06% |
| BBVA Asset Management SA SGIICas of 30 Jun 2024 | 1.76k | 0.02% |
| Deka Investment GmbHas of 30 Jun 2024 | 509.00 | 0.01% |
| DWS Investment GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Oct 2024Source: FactSet Research Systems Inc.
